Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

June 15, 2026

Study Completion Date

December 30, 2026

Conditions
Refractory/Relapsed Acute Myeloid Leukaemia
Interventions
DRUG

autologous FL-33 CAR T therapy

Autologous FL-33 CAR T cells are infused intravenously.

DRUG

prior-HSCT donor-derived FL-33 CAR T therapy

Prior-HSCT donor-derived FL-33 CAR T cells are infused intravenously.

DRUG

Newly matched donor-derived FL-33 CAR T therapy

Newly matched donor-derived FL-33 CAR T cells are infused intravenously

Trial Locations (4)

200435

NOT_YET_RECRUITING

Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, Shanghai

201418

NOT_YET_RECRUITING

Shanghai Liquan Hospital, Shanghai

610083

NOT_YET_RECRUITING

The General Hospital of Western Theater Command PLA, Chengdu

Unknown

RECRUITING

BeijingGoBroadH, Beijing

All Listed Sponsors
collaborator

The General Hospital of Western Theater Command

OTHER

collaborator

Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

OTHER

collaborator

Shanghai Liquan Hospital

OTHER

lead

Beijing GoBroad Hospital

OTHER